French drug company Sanofi-Aventis announced that the US Food and Drug Administration (FDA) had approved its heart drug and potential blockbuster product Multaq. Multaq promotes a normal heart rhythm in people with atrial fibrillation or atrial flutter. These conditions cause the heart to beat too quickly and can prevent it from pumping blood correctly.